Wearable On-Body Injectors Market
完整報告名稱與涵蓋範圍
Wearable On-Body Injectors Market Size, Share & Trends Analysis Report, By Device Type (Disposable Prefilled On-Body Injectors, Reusable and Electromechanical Wearable Injectors, Bolus and Large-Volume Patch Injectors, Connected and Smart Wearable Injectors), By Fill Volume (Up to 5 mL, 5 mL to 10 mL, Above 10 mL), By Therapeutic Application (Oncology Supportive Care and Biologics, Immunology and Autoimmune Therapies, Cardiometabolic and Rare Disease Therapies, Other Chronic and Specialty Therapies), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The wearable on-body injectors market covers disposable prefilled and reusable electromechanical devices worn on the body to deliver subcutaneous doses too large or too slow for handheld autoinjectors, including bolus and large-volume patch injectors and connected smart devices, across oncology supportive care, immunology, cardiometabolic, rare disease and other chronic therapies. Handheld autoinjectors, pen injectors, insulin patch pumps and infusion pumps are excluded but analysed as adjacent delivery options.
Growth is driven by the conversion of intravenous biologics to subcutaneous formulations, which requires delivery of several millilitres over minutes, by pharmaceutical companies seeking to move treatment from infusion centers to homes, by lifecycle strategies for blockbuster biologics and by high-concentration formulations enabled by hyaluronidase and viscosity technologies. Device platforms compete on volume and viscosity range, wear time, primary container compatibility, reusability and sustainability, connectivity and the regulatory track record of combination product approvals, while pharmaceutical partners weigh development timelines and manufacturing scale. Reusable electromechanical designs reduce waste and cost per dose for chronic therapies, and integration with digital adherence platforms adds service value.
North America and Europe lead adoption through approved combination products, with Japan and China following as biologics and self-administration expand. Competition involves drug delivery platform companies, pharmaceutical packaging groups and electromechanical device specialists.
The InsightAce study provides US$ revenue forecasts for every device type, fill volume, therapeutic application and end user and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Wearable On-Body Injectors Market Snapshot
Chapter 4. Global Wearable On-Body Injectors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Device Type Estimates & Trend Analysis
5.1. Device Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Device Type:
5.2.1. Disposable Prefilled On-Body Injectors
5.2.2. Reusable and Electromechanical Wearable Injectors
5.2.3. Bolus and Large-Volume Patch Injectors
5.2.4. Connected and Smart Wearable Injectors
Chapter 6. Market Segmentation 2: By Fill Volume Estimates & Trend Analysis
6.1. Fill Volume & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Fill Volume:
6.2.1. Up to 5 mL
6.2.2. 5 mL to 10 mL
6.2.3. Above 10 mL
Chapter 7. Market Segmentation 3: By Therapeutic Application Estimates & Trend Analysis
7.1. Therapeutic Application & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Therapeutic Application:
7.2.1. Oncology Supportive Care and Biologics
7.2.2. Immunology and Autoimmune Therapies
7.2.3. Cardiometabolic and Rare Disease Therapies
7.2.4. Other Chronic and Specialty Therapies
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical and Biotechnology Companies
8.2.2. Home Users and Patients
8.2.3. Hospitals and Infusion Centers
Chapter 9. Wearable On-Body Injectors Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Enable Injections, Inc.
11.2. West Pharmaceutical Services, Inc.
11.3. Ypsomed AG
11.4. Becton, Dickinson and Company
11.5. SHL Medical AG
11.6. Gerresheimer AG
11.7. Stevanato Group S.p.A.
11.8. Insulet Corporation
11.9. Sonceboz SA
11.10. Bespak (Recipharm)
11.11. Nemera
11.12. Subcuject ApS
11.13. LTS Lohmann Therapie-Systeme AG
11.14. Eitan Medical Ltd.
11.15. Phillips-Medisize (Molex, Koch Industries)
圖表清單 List of Tables & Figures
Table 1. Global Wearable On-Body Injectors Revenue Forecast by Device Type, 2026-2035 (US$ Mn)
Figure 1. Global Wearable On-Body Injectors Market Snapshot, 2026 & 2035
Table 2. Global Wearable On-Body Injectors Revenue Forecast by Fill Volume, 2026-2035 (US$ Mn)
Figure 2. Global Wearable On-Body Injectors Market Share by Fill Volume, 2026 & 2035
Table 3. Global Wearable On-Body Injectors Revenue Forecast by Therapeutic Application, 2026-2035 (US$ Mn)
Figure 3. Intravenous-to-Subcutaneous Conversion Pipeline Driving On-Body Injector Demand, 2026-2035
Table 4. Global Wearable On-Body Injectors Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Disposable Versus Reusable Electromechanical Platform Economics and Sustainability
Table 5. North America Wearable On-Body Injectors Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Wearable On-Body Injectors Growth Opportunity Analysis
Table 6. Europe Wearable On-Body Injectors Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Combination Product Approvals Using On-Body Injectors by Therapeutic Area
Table 7. Asia Pacific Wearable On-Body Injectors Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Wearable On-Body Injectors Market Participants
Table 8. Latin America and Middle East & Africa Wearable On-Body Injectors Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們